Novartis Venture Fund and Forbion led a $130m Series B funding round in Protego Biopharma.

Novartis Venture Fund, a corporate venture capital investor, and Forbion, a venture capital firm, led a $130m Series B funding round in Protego Biopharma, a biotechnology company developing small molecule therapeutics for protein misfolding disorders, with participation from Omega Funds, Droia Ventures, YK Bioventures, Digitalis Ventures, Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research. "We are deeply grateful for the steadfast support of our existing investors, who have believed in us through every stage, and we are pleased to welcome leading global investors to join us on this journey. Their confidence underscores the promise of our science and the urgency of our mission. With the capital raised, we are positioned to advance PROT-001 into pivotal trials, moving closer to delivering the first disease-modifying therapy for AL amyloidosis and offering new hope to patients who currently face devastating outcomes," Brent Warner, Protego Biopharma CEO.